Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has announced a definitive agreement to acquire APEIRON Biologics AG for $100 million in cash. APEIRON holds royalty rights to QARZIBA® (dinutuximab beta), a treatment…
Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has…
Epsilogen Receives CTA Approval for Phase Ib Trial of MOv18 IgE in Platinum-Resistant Ovarian Cancer Epsilogen has announced that it has received Clinical Trial Authorization (CTA) approval for a Phase…
The Severe Acute Respiratory Infections Network (SARInet) is a regional collaboration comprising professionals from hospitals, laboratories, health organizations, and institutions across Member States of the Americas. SARInet, coordinated by the…
Country-level preparedness for influenza pandemics is crucial to mitigate global spread and its associated impacts on health and economies. Pandemics can cause widespread illness, high mortality rates, and substantial economic…
Analysis of Recent Influenza Cases The World Health Organization (WHO) has recently issued several Disease Outbreak News reports detailing cases of influenza, highlighting significant developments in detection, sources of exposure,…
Global Summit in Kathmandu Advances Efforts Towards Sustainable Sanitation Goals From June 25–27, 2024, delegates representing over 20 countries and various stakeholder organizations convened in Kathmandu for a pivotal Global…
Neuranics, a pioneering deep tech startup based in Glasgow, proudly announced its prestigious accolade as the Deep Tech Investment of the Year at the UK Angel Investment Awards. The ceremony,…
Axena Health Secures Expanded Insurance Coverage for Leva Pelvic Health System Axena Health, Inc. (Axena Health) has achieved a significant milestone in expanding insurance coverage for its Leva® Pelvic Health…
The latest addition to ResearchAndMarkets.com’s offerings is the “Hospital Care Collaboration and Licensing Deals 2016-2024” report, now fully revised and updated. This comprehensive report delves into hospital care deals spanning…
The “Collaboration Deals in Pharmaceuticals 2019-2024” report is now available on ResearchAndMarkets.com. This report offers a detailed analysis of collaboration deals in the pharmaceutical industry, explaining why and how companies…
Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or “Company”), a clinical-stage biotechnology firm developing advanced targeted virotherapies, has announced that its Board of Directors has approved a 1-for-10 reverse stock…